ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors
ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors
复制标题
DOI：
10.1038/nrc1667
复制
发表时间：
2005-07
影响因子：
78.5
通讯作者：
N. Hynes;H. Lane
中科院分区：
文献类型：
--
作者：
N. Hynes;H. Lane
ERBB受体酪氨酸激酶在人类癌症中具有重要作用。特别是，表皮生长因子受体和ERBB 2的表达或活化在许多上皮肿瘤中发生改变，临床研究表明它们在肿瘤病因学和进展中具有重要作用。因此，这些受体已被深入研究，以了解其在癌症生物学中的重要性和作为治疗靶点，许多ERBB抑制剂现在用于临床。我们将讨论这些受体作为临床靶点的意义，特别是反应的分子机制。
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.